MARKET

MDGL

MDGL

Madrigal Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

108.47
-0.90
-0.82%
After Hours: 108.47 0 0.00% 16:00 07/07 EDT
OPEN
109.14
PREV CLOSE
109.37
HIGH
112.92
LOW
108.45
VOLUME
99.86K
TURNOVER
--
52 WEEK HIGH
127.25
52 WEEK LOW
56.82
MARKET CAP
1.67B
P/E (TTM)
-15.9241
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MDGL stock price target is 176.29 with a high estimate of 300.00 and a low estimate of 104.00.

EPS

MDGL News

More
Should You Avoid Madrigal Pharmaceuticals, Inc. (MDGL)?
Insider Monkey · 06/28 03:19
Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals
MotleyFool.com · 06/18 04:00
Many 'Ifs' Surrounding Viking Therapeutics
GuruFocus.com · 06/15 22:19
Madrigal Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating
Investor's Business Daily · 06/15 20:56
3 Top Biotech Stocks to Buy in June
Motley Fool · 06/06 17:29
BMO Capital Initiates Coverage On Madrigal Pharmaceuticals with Market Perform Rating, Announces Price Target of $135
BMO Capital analyst Matthew Luchini initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Perform rating and announces Price Target of $135.
Benzinga · 06/05 10:46
We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth
Simply Wall St. · 05/28 13:07
The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26)
Benzinga · 05/27 11:25

Industry

Biotechnology & Medical Research
+1.75%
Pharmaceuticals & Medical Research
-0.01%

Hot Stocks

Symbol
Price
%Change

About MDGL

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
More

Webull offers kinds of Madrigal Pharmaceuticals Inc stock information, including NASDAQ:MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.